Arturo Md Molina
CIK 1398940 · Chief Medical Officer · last filed 2026-03-27
Arturo Md Molina is a Chief Medical Officer who has filed 42 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for PTGX, was dated Mar 27, 2026. Across all open-market trades the lifetime net is −$8.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $12.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PTGX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LOS ANGELES, CA 90024
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTGX | Chief Medical Officer | 99,115 | $128.75 | $12.76M | -$8.84M | 15 | 2026-03-27 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 0 | $20.01 | $0 | $0 | 3 | 2022-10-14 |
| STRO | Chief Medical Officer | 3,774 | $10.94 | $41.3K | $50.0K | 11 | 2022-03-07 |
| Cougar Biotechnology, Inc. (CGRB) Delisted | Chief Medical Officer | — | — | — | $0 | 2 | 2009-07-07 |
Recent Filings
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-27 | PTGX | Mixed | — | -$1.45M | EDGAR |
| 2026-03-26 | PTGX | Notice (144) | −15,000 | -$1.57M | EDGAR |
| 2026-01-27 | PTGX | Notice (144) | −5,000 | -$410.0K | EDGAR |
| 2026-01-27 | PTGX | Mixed | −13,151 | -$1.82M | EDGAR |
| 2026-01-26 | PTGX | Notice (144) | −5,000 | -$411.4K | EDGAR |
| 2026-01-23 | PTGX | Notice (144) | −13,151 | -$1.10M | EDGAR |
| 2026-01-21 | PTGX | Sell (S) | −9,514 | -$784.7K | EDGAR |
| 2026-01-21 | PTGX | Notice (144) | −9,514 | -$784.7K | EDGAR |
| 2026-01-06 | PTGX | Grant (A) | +25,600 | $0 | EDGAR |
| 2025-11-19 | PTGX | Sell (S) | −2,712 | -$229.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.